How to Enhance Antigen Test Kit Performance through Optimized Antibody Pairing?

I. Why is Antigen Testing So Crucial in Pandemic Control?

Against the backdrop of the ongoing global COVID-19 pandemic, antigen testing technology has gained significant attention from various countries due to its unique advantages. In August 2020, the U.S. government announced the procurement of 150 million COVID-19 antigen test kits, a decision that underscores the important role of antigen testing in pandemic control. The U.S. Food and Drug Administration had previously granted Emergency Use Authorization for portable COVID-19 antigen test kits from relevant companies, with health officials hailing them as a "game-changer."

Compared to nucleic acid testing, antigen testing offers significant advantages such as simple operation, rapid results, and low cost. Compared to antibody testing, antigen testing is not limited by a serological window period and can promptly detect individuals who have just developed infection symptoms. These characteristics make it an important complement to nucleic acid testing, particularly suitable for large-scale screening and use in primary healthcare institutions.

The Chinese government also places high importance on the development of antigen testing technology. During a State Council policy briefing, relevant officials from the Ministry of Science and Technology clearly stated that they would prioritize support for the development of antigen test kits to enrich China's testing technology system. This policy direction has created favorable conditions for the advancement of antigen testing technology

II. How Do Paired Antibodies Determine the Performance of Antigen Test Kits?

The core performance of an antigen test kit largely depends on the paired antibodies it uses. Paired antibodies refer to two monoclonal antibodies that can specifically recognize different epitopes on the same antigen molecule; one serves as the capture antibody and the other as the detection antibody. The design principle of this double-antibody sandwich assay dictates that the quality of the paired antibodies is directly related to the assay's sensitivity and specificity.

High-quality paired antibodies can significantly enhance test kit performance. Ideally, paired antibodies should possess high affinity, high specificity, and good stability. Among them, the capture antibody needs to effectively bind to the solid-phase carrier while maintaining its antigen-binding capacity; the detection antibody needs to retain high antigen-recognition capability after labeling. The two work synergistically to ensure the accuracy and reliability of the detection.

In practical applications, screening for optimal paired antibodies is a complex yet critical process. Developers need to identify the best combination from a large pool of candidate antibodies, considering factors such as the antibodies' affinity for the target antigen, non-interference of the recognized epitopes, and synergistic effects within the detection system. These factors collectively determine the final product's performance.

III. How to Establish a Scientific Evaluation Method for Paired Antibodies?

Establishing a scientific evaluation system is crucial for accurately assessing the performance of paired antibodies. The currently most recognized method involves using inactivated SARS-CoV-2 culture for evaluation. This method can simulate the real detection environment to the greatest extent while ensuring biosafety.

Inactivated virus culture offers multiple advantages: Firstly, it preserves the natural conformation of viral proteins, allowing a true reflection of the paired antibodies' ability to bind the native antigen. Secondly, after treatment with lysis buffer, it can simulate the state of the antigen during the actual detection process. Finally, this method offers good reproducibility and potential for standardization, facilitating result comparison between different laboratories.

During implementation, the evaluation system should include assessment metrics across multiple dimensions. Beyond basic sensitivity, it should also include parameters such as specificity, cross-reactivity, and stability. Simultaneously, standardized operating procedures and quality control standards need to be established to ensure the comparability and reliability of evaluation results.

Furthermore, a stepwise evaluation strategy is recommended: preliminary screening using recombinant proteins, followed by verification using inactivated virus culture, and finally, performance confirmation through clinical trials. This multi-tiered evaluation system can effectively improve the success rate of paired antibody screening and reduce development risks.

IV. What is the Development Prospect for Paired Antibody Technology?

The advancement of paired antibody technology is not only significant for COVID-19 pandemic control but also accumulates valuable experience for future infectious disease prevention and control work. Through the development of COVID-19 antigen detection products, relevant companies have established more comprehensive technical systems in areas such as paired antibody screening, process optimization, and quality evaluation.

These technological accumulations can be extended to other infectious disease detection fields, providing technical support for building a more robust infectious disease surveillance network. For instance, rapid detection products for common pathogens like influenza virus and respiratory syncytial virus can benefit from the technical experience gained in COVID-19 antigen testing.

Meanwhile, with advancements in monoclonal antibody technology and protein engineering, the performance of paired antibodies will be further enhanced. Through rational design and directed evolution, researchers can develop antibody variants with higher affinity and better stability, thereby driving technological progress across the entire detection industry.

V. Which Companies Supply Paired Antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed the "SARS-CoV-2 Nucleocapsid Protein Recombinant Rabbit Monoclonal Antibody" (Product Code: S0B3009). This is a paired antibody reagent characterized by high affinity, high specificity, and excellent pairing compatibility. Developed using a recombinant rabbit monoclonal antibody technology platform and validated by various methods including ELISA and immunochromatography, it holds key application value in areas such as SARS-CoV-2 antigen detection, virology research, and vaccine evaluation.

Core Product Advantages:

• Excellent Pairing Performance and High Affinity: Rigorously validated through pairing screening, this product can simultaneously bind to different epitopes of the SARS-CoV-2 nucleocapsid protein, demonstrating exceptional pairing compatibility and nanomolar-level high affinity, laying the foundation for developing high-sensitivity detection reagents.
• High Specificity and Low Cross-Reactivity: The product exhibits highly specific recognition capability for the SARS-CoV-2 nucleocapsid protein, with no cross-reactivity with common coronaviruses, ensuring highly accurate and reliable test results.

Suitable for Various Key Application Scenarios: This product is an ideal tool for the following areas:

• Immunoassay Reagent Development: Serves as a core raw material for developing SARS-CoV-2 antigen detection ELISA kits, immunochromatographic test strips, and chemiluminescence detection platforms.
• Virology and Pathogenesis Research: Used for studying viral replication and assembly processes within cells and analyzing protein expression levels.
• Drug and Vaccine Potency Evaluation: Used for antiviral drug screening, monitoring antigen expression levels post-vaccination, and neutralization antibody evaluation studies.
• Environmental and Biological Sample Monitoring: Used for monitoring and assessing viral load in environmental samples, aerosols, and other media.

Professional Technical Support: We provide detailed product technical documentation, including complete pairing validation data, sensitivity analysis reports, and professional application development solutions, fully committed to assisting customers in accelerating their development processes in the field of SARS-CoV-2 detection and related research.

Hangzhou Start Biotech Co., Ltd. is consistently dedicated to providing high-quality, high-value biological reagents and solutions for global innovative pharmaceutical companies and research institutions. For more details about the "SARS-CoV-2 Nucleocapsid Protein Recombinant Rabbit Monoclonal Antibody" (Product Code S0B3009) or to request a sample test, please feel free to contact us.

Product Information